{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-05-20T22:10:40.117Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   50-59   Skip unless catalyst <30d + insider cluster\n   < 50    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   < 60    Skip (no exception; small caps need a clear catalyst)\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"AUPH\",\n  \"company\": \"Aurinia Pharmaceuticals Inc.\",\n  \"investigation_summary\": \"Aurinia is a profitable biotech commercializing LUPKYNIS (voclosporin) for lupus nephritis. The investigation was triggered by Kevin Tang's Form 4 open-market purchase cluster in Feb-Mar 2026 (~900,000 shares at $13.90–$14.38 via his LP funds), followed by the March C-suite takeover (Tang named CEO, Hearne CFO, Cole COO). That cluster is verified P-code insider buying — the most significant signal on the stock. The company just closed the Kezar Life Sciences acquisition (May 8, 2026) for $41M, adding pipeline assets and triggering a CVR structure with potential milestone payments tied to zetomipzomib development or licensing. Q1 2026 earnings beat by 27%; forward P/E of ~14x is modest relative to biotech peers; FCF yield is strong at ~6%. The May 18, 2026 Form 4 grants (PSU awards with price-target vesting conditions) from new executives are equity compensation, not cash purchases — they signal alignment but aren't the open-market buy cluster that triggered this investigation. Options IV of 47–67% supports covered-call or strangle strategies near earnings.\",\n  \"verdict\": \"promising\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"long_stock\",\n    \"csp\",\n    \"cc\"\n  ],\n  \"business_snapshot\": \"Aurinia Pharmaceuticals is a commercial-stage biotech with $298M in LUPKYNIS (voclosporin) revenue for FY2025, growing 24% YoY. The drug is the first and only FDA-approved oral therapy for active lupus nephritis — a orphan indication with high unmet need affecting ~200–300k patients in the US. Gross margins are ~78%, operating income was $41M in Q1 2026 alone (vs. $22M in Q1 2025), and the company is FCF-positive. Aurinia operates a dedicated Monoplant manufacturing facility via Lonza (finance lease, ~$65M liability) providing supply security for voclosporin. On May 8, 2026, it completed acquisition of Kezar Life Sciences through a tender offer ($41.2M, ~80% acceptance), absorbing Kezar's pipeline including zetomipzomib (autoimmune) with associated CVR upside potential tied to licensing or clinical milestones worth up to $88M. The March 2026 C-suite overhaul placed Kevin Tang — the company's largest shareholder through Tang Capital Partners (~12.2M shares, ~9.5% ownership) — as CEO, signaling active investor intent on value creation.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [\n        {\n          \"insider\": \"Kevin Tang\",\n          \"role\": \"Director / Newly Appointed CEO (Tang Capital founder)\",\n          \"amount_usd\": 12500000,\n          \"date\": \"2026-02-27 to 2026-03-03\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000117857926000001/xslF345X05/form4-03032026_100309.xml\"\n        },\n        {\n          \"insider\": \"Stephen P. Robertson\",\n          \"role\": \"Chief Legal Officer (new grant)\",\n          \"amount_usd\": 0,\n          \"date\": \"2026-05-18\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000183779826000005/xslF345X06/wk-form4_1779311116.xml\"\n        },\n        {\n          \"insider\": \"Michael Hearne\",\n          \"role\": \"CFO (new grant)\",\n          \"amount_usd\": 0,\n          \"date\": \"2026-05-18\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000175991026000004/xslF345X06/wk-form4_1779311085.xml\"\n        },\n        {\n          \"insider\": \"Ryan Cole\",\n          \"role\": \"COO (new grant)\",\n          \"amount_usd\": 0,\n          \"date\": \"2026-05-18\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000212696626000003/xslF345X06/wk-form4_1779311027.xml\"\n        }\n      ],\n      \"insider_open_market_total_usd_90d\": 12500000,\n      \"distinct_insider_buyers_90d\": 1,\n      \"ceo_buy_present\": true,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 0,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-07-30T12:30:00.000Z\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026 beat by +27% (EPS $0.25 vs est. $0.1975); Q4 2025 anomaly beat (+606%) partially due to one-time items; Q3 2025 beat +44%; consistent positive surprise pattern over past 4 quarters\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 2026 earnings (July 30) — will include Kezar integration update and updated full-year guidance. Q1 showed $73.6M net product sales, +23% YoY.\",\n          \"date_or_window\": \"2026-07-30\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/aurinia-pharmaceuticals-auph-q1-earnings-151503427.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"m&a\",\n          \"description\": \"Kezar Life Sciences acquisition closed May 8, 2026 — ~$41M cash outlay. Pipeline addition of zetomipzomib + CVR with potential $88M milestone payments for Legacy Assets.\",\n          \"date_or_window\": \"Completed May 8, 2026; integration ongoing through Q2\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/ef20072568_8k.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"guidance\",\n          \"description\": \"FY2026 guidance: total revenue $315M-$325M; net product sales $305M-$315M. Q1 actuals ($77.7M) were in line with seasonal trajectory.\",\n          \"date_or_window\": \"Issued Feb 26, 2026 for FY2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/news/aurinia-surging-2025-earnings-upbeat-002221843.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 14.22,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": 10.99,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 6.09,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"Forward P/E of 14x is modest for a profitable commercial-stage biotech with 24% revenue growth and dominant market position in oral lupus nephritis. Biotech peers with similar revenue scale and growth trade at 16-22x forward earnings. The stock has run +30% YTD but sits only ~6% below the 52-week high — not extended relative to fundamentals or guidance.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": 0,\n      \"net_debt_to_ebitda\": -1.42,\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 53.2,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 15.9,\n    \"ytd_return_pct\": 30.11,\n    \"from_52w_high_pct\": -5.8\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000017/auph-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 revenue $283M (+29% YoY); FY2025 net income $287.2M (includes tax benefit from DTA release). LUPKYNIS net product sales drove growth. OpEx efficiency improving as SG&A leverage kicks in.\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-07\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000049/auph-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: $73.6M LUPKYNIS net product sales (+23% YoY), total revenue $77.7M; operating income $41.4M vs $21.8M in Q1 2025; EPS $0.25 (diluted). Cash + investments $378.8M. Acquired Kezar via merger agreement announced March 30, closed May 8.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-03-23\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000026/auph-20260320.htm\",\n      \"key_takeaways\": [\n        \"C-suite overhaul: Kevin Tang (Tang Capital founder, largest shareholder) appointed CEO; Michael Hearne as CFO; Ryan Cole as COO. Former CEO Peter Greenleaf and others exited.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-03-30\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000035/auph-20260330.htm\",\n      \"key_takeaways\": [\n        \"Definitive merger agreement to acquire Kezar Life Sciences for $6.955 cash + one CVR per share; total equity value ~$41M tendered amount. Tang Capital (Kevin Tang) already owned ~9% of Kezar and entered a Tender and Support Agreement.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-11\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/ef20072568_8k.htm\",\n      \"key_takeaways\": [\n        \"Kezar acquisition completed May 8, 2026. 5,927,580 shares tendered (80.24% of outstanding). Merger effective May 11. CVR Agreement filed with rights to receive zetomipzomib milestone/royalty payments.\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-10-16\"\n    ],\n    \"iv_summary\": \"ATM IV ~47% (June expiry, 28 DTE); OTM call skew slightly elevated vs ATM; put skew normal. Oct expiry shows higher IV (~51-75%) reflecting earnings uncertainty around July 30 date.\",\n    \"notable_skew_or_flow\": \"Near-term calls dominate volume: Jun 16c/17c/18c have high open interest. Put/call ratio of 0.04 with net call notional bias of +$18K suggests bullish directional positioning. No whale blocks detected on crude UOA feed.\"\n  },\n  \"competitive_landscape\": \"Aurinia's LUPKYNIS faces no direct oral competitor in lupus nephritis — Benlysta (IV, GSK) is the main alternative; Aurora/Kezar pipeline programs are earlier-stage and would take years to compete directly. Aurinia's ~78% gross margin reflects pricing power from an orphan-designation drug with limited payer leverage.\",\n  \"key_risks\": [\n    \"Kezar integration risk: zetomipzomib clinical development requires capital deployment post-close; CVR value uncertain\",\n    \"Concentration in single product (LUPKYNIS) — any safety signal, reimbursement pressure or competitive entry would be material\",\n    \"Monoplant finance lease ($64.7M liability) creates ongoing fixed cost commitment through 2030\",\n    \"Aggressive share repurchases ($211M spent to date under the $300M authorization) are shrinking cash but also boosting per-share economics\",\n    \"No dividend; purely a capital appreciation story dependent on continued revenue growth\"\n  ],\n  \"what_the_market_might_be_missing\": \"The March 2026 Form 4 cluster from Kevin Tang was an open-market purchase of ~900,000 shares (P-code) at $13.90–$14.38 in late February/early March — BEFORE the public announcement of his CEO appointment on March 23. The filing shows he accumulated these shares just before the market understood the significance of the management takeover. This is a textbook pre-announcement insider accumulation pattern, where the market has since partially re-rated the stock (from ~$14 to $15.90) but may not fully price in what Tang Capital's operational control implies for capital allocation decisions — including potential further buybacks, pipeline investments from Kezar CVR proceeds, or strategic M&A at potentially attractive valuations given current price proximity to 52-week high.\",\n  \"anti_signals\": [\n    \"concentration\",\n    \"dilution\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Q1 2026 10-Q (primary financial source)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000049/auph-20260331.htm\"\n    },\n    {\n      \"label\": \"Kevin Tang Form 4 — Feb/Mar 2026 open-market purchases (critical signal)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000117857926000001/xslF345X05/form4-03032026_100309.xml\"\n    },\n    {\n      \"label\": \"Kezar acquisition close 8-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/ef20072568_8k.htm\"\n    },\n    {\n      \"label\": \"Merger agreement 8-K (Tang Capital support + Kezar CVR structure)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000035/auph-20260330.htm\"\n    },\n    {\n      \"label\": \"C-suite management transition 8-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000026/auph-20260320.htm\"\n    },\n    {\n      \"label\": \"Q1 earnings results press release\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/aurinia-pharmaceuticals-reports-financial-results-120000475.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-05-20T22:11:43.294Z",
      "raw_content": "<think>The dossier is for AUPH (Aurinia Pharmaceuticals Inc.).\nLet's score it according to the rubric.\n\nA. SMART-MONEY CLUSTER (max 25)\n- 10 pts: 1 distinct insider (Kevin Tang) with open-market purchases > $500K ($12.5M). Wait, the rubric says \"3+ distinct insiders\". So 0 pts for the first 10.\n- +3 pts: CEO is among buyers (Kevin Tang is newly appointed CEO and buyer). +3\n- +3 pts: CFO is among buyers? No, Hearne is CFO but amount_usd is 0. So 0.\n- +2 pts: total purchases > $5M? Yes, $12.5M. +2\n- 5 pts: known concentrated 13F? pending. 0.\n- +3 pts: top-3 positions? Not mentioned. 0.\n- 2 pts: politician buy? pending. 0.\n- +1 pt: multiple unrelated members? No.\n- Penalty: 0.\nTotal A: 3 + 2 = 5. (Wait, only 1 distinct buyer. The rubric says \"10 pts if 3+ distinct insiders... totaling >= $500K\". Since it's only 1, I give 0 for that base, but maybe I should give partial? The rubric is strict: \"10 pts if 3+ distinct insiders\". I'll stick to 5.)\n\nB. OPTIONS FLOW / UOA (max 10)\n- 4 pts: whale_call_blocks_otm >= 2? No, \"No whale blocks detected\". 0.\n- 3 pts: bullish IV skew? \"OTM call skew slightly elevated vs ATM\". Maybe 1 pt.\n- 2 pts: net_dollar_bias_pct > 30? Net call notional +$18K. Not >30%. 0.\n- 1 pt: large OI at defended level? \"Jun 16c/17c/18c have high open interest.\" Maybe 1 pt.\nTotal B: 2.\n\nC. CATALYST (max 25)\n- 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%? Yes, Q2 earnings July 30, last 4 quarters positive surprise. +10\n- 8 pts: pending product launch / FDA / contract? No.\n- 5 pts: recent guidance raise? No, issued Feb 26.\n- 5 pts: quantifiable sector tailwind? No.\nTotal C: 10.\n\nD. MISPRICING (max 15)\n- 5 pts: forward P/E >= 20% below sector median? Sector median null. Narrative says \"modest for a profitable commercial-stage biotech... trade at 16-22x\". 14x is ~14-30% below 16-22x. Let's give 3 pts.\n- 4 pts: EV/EBITDA >= 30% below sector median? Sector median null. 0.\n- 4 pts: FCF yield >= 7%? It's 6.09%. Close, but <7. 0.\n- 5 pts: SOTP gap >= 25%? null. 0.\nTotal D: 3.\n\nE. QUALITY (max 15)\n- 5 pts: ROIC >= 15%? null. 0.\n- 5 pts: gross margin expanding >= 3pp YoY? 0 pp. 0.\n- 5 pts: net debt / EBITDA <= 2x? -1.42 (net cash). +5.\nTotal E: 5.\n\nF. MOMENTUM/TECHNICAL (max 10)\n- 3 pts: above both 50DMA and 200DMA? Yes. +3\n- 4 pts: 12-1 month price return positive AND beating sector? 12-1 month return not given, but YTD +30%. Not enough info. 0.\n- 2 pts: RSI 14 in 40-65? 53.2. +2\n- 1 pt: MACD bullish cross? false. 0.\nTotal F: 5.\n\nTotal Score: 5 + 2 + 10 + 3 + 5 + 5 = 30.\nWait, let's re-evaluate Smart Money. The rubric says \"10 pts if 3+ distinct insiders...\". It's only 1. So 0. But CEO is buyer (+3), total > $5M (+2). So 5.\nCould I give partial credit? Usually, rubrics are strict. I'll stick to 5.\nWhat about Catalyst? Earnings within 90 days (July 30) and 4 quarters > 0%. That's 10 pts.\nMispricing: FCF yield 6.09% (close to 7, maybe 2 pts?). Forward P/E 14.22 vs biotech median ~20x (10-20% below). I'll give 3.\nQuality: Net debt/EBITDA -1.42 -> +5.\nTechnical: Above 50/200DMA (+3), RSI 53.2 (+2) = 5.\nTotal: ~30.\n\nRisk Class: market_cap is not explicitly given, but AUPH is a small/mid cap biotech (~$200M market cap based on $15.9 price and ~12.5M shares outstanding? Wait, 12.2M shares is Tang's stake. Total shares ~15M? Market cap ~$240M. So ASYMMETRIC.)\nThresholds for ASYMMETRIC: <60 Skip.\nAnti-signals: concentration, dilution. Concentration risk is noted (single product). Dilution? \"Aggressive share repurchases... shrinking cash\". Not dilution. But anti_signals list has \"concentration\", \"dilution\". The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nConcentration: Single product (LUPKYNIS). This is a real risk for a biotech, but maybe not a hard gate unless >30% customer concentration. The dossier says \"concentration\" in anti_signals. I will note it but the score is already <60.\nDilution: They are doing buybacks, not dilution. I'll clarify.\n\nGiven the score is ~30, it's well below the 60 threshold for asymmetric. I will skip.\nReason: Low score due to lack of institutional smart-money clustering (only 1 insider buyer), minimal options flow confirmation, and absence of quantifiable mispricing or quality metrics. While insider buying and pre-earnings momentum are present, the dossier lacks the breadth of catalysts and structural support required to clear the asymmetric threshold.\n\nLet's double check the scoring.\nA: CEO buy (+3), >$5M total (+2) = 5.\nB: IV skew slightly elevated (+1), OI at Jun strikes (+1) = 2.\nC: Earnings within 90d + 4q positive surprise = 10.\nD: FCF yield 6.09% (close to 7, maybe 2), Forward PE 14x vs ~20x peer (maybe 3) = 5.\nE: Net cash (-1.42 debt/EBITDA) = 5.\nF: Above 50/200 DMA (+3), RSI 40-65 (+2) = 5.\nTotal: 32.\n\nScore breakdown:\nsmart_money: 5\noptions_flow: 2\ncatalyst: 10\nmispricing: 5\nquality: 5\ntechnical: 5\nComposite: 32\n\nReason: Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. The single-product concentration risk and absence of sustained options flow further limit the setup's robustness.\n\nCheck thresholds: ASYMMETRIC < 60 Skip.\nOutput matches skip format.\nI will generate the JSON.\nOne minor thing: The prompt says \"If scoring_inputs has anti_signals_present non-empty...\". The dossier has `\"anti_signals\": [\"concentration\", \"dilution\"]`. I should mention that dilution is actually a buyback program (negative dilution), and concentration is inherent to early commercial biotech but mitigated by orphan status and pricing power, though it doesn't save the low score.\n\nAll good. Proceeding. \nOutput matches required schema.\nI will carefully format the JSON.\nScore: 32\nBreakdown: smart_money: 5, options_flow: 2, catalyst: 10, mispricing: 5, quality: 5, technical: 5\nReason: \"Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. The single-product concentration risk and absence of sustained options flow further limit the setup's robustness.\"\nReady. \nSelf-Correction/Refinement during thought: \nWait, the rubric for A says \"10 pts if 3+ distinct insiders... totaling ≥ $500K\". It's all or nothing for that 10 pts. So 0.\nCEO +3, CFO +0, >$5M +2. Total A = 5.\nCatalyst: Earnings within 90d + 4q positive = 10.\nMispricing: FCF 6.09% (just under 7, maybe 2 pts), P/E 14.2 vs sector ~20 (maybe 3 pts). Total D = 5.\nQuality: Net debt/EBITDA -1.42 -> +5.\nTechnical: Above 50/200 -> +3, RSI 53.2 -> +2. Total F = 5.\nOptions: Skew +1, OI +1. Total B = 2.\nTotal = 32. Matches.\nI will output the skip JSON.\nOne detail: \"dilution\" in anti_signals. I'll address it briefly in the reason or just stick to the score rationale. The prompt says \"skip unless you can articulate WHY it doesn't apply\". I'll add a brief note about dilution being negated by the active $300M buyback program, but the score remains low regardless.\nActually, the prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will explicitly state that dilution is negated by the aggressive buyback authorization, and concentration is standard for this stage but doesn't change the low score.\nI'll keep the reason concise as requested.\nOutput matches format.\nProceed. \nJSON structure:\n{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 5,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. Dilution risk is negated by an active $300M buyback program, but the setup lacks the breadth of catalysts and structural support required to clear the bar.\"\n}\nAll good. Output matches. \nOne check: \"dilution\" anti-signal. The dossier says \"Aggressive share repurchases ($211M spent to date under the $300M authorization) are shrinking cash but also boosting per-share economics.\" So dilution is actually negative (accretion). I'll note that.\nFinal check of the prompt: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" -> I will articulate it in the reason.\nReady. \nOutput matches exactly. \nProceeds. \n[Output Generation] -> JSON only. \n(Self-Correction/Verification during drafting)\nWait, let's look at the Smart Money rubric again: \"10 pts if 3+ distinct insiders with open-market purchases (code P) in last 90 days totaling ≥ $500K\". It's strict. I gave 0.\nBut the CEO is among buyers (+3). Total > $5M (+2). So 5. Correct.\nCatalyst: 10. Correct.\nMispricing: 5. Correct.\nQuality: 5. Correct.\nTechnical: 5. Correct.\nOptions: 2. Correct.\nTotal 32.\nMatches threshold for asymmetric: <60 Skip.\nAll good.\nOutput matches requested format.\nProceeds. \n[Output Generation] -> JSON. \n(Note: I will ensure the JSON is strictly valid and contains no markdown fences as requested: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\")\nDone. \nProceeds. \n```json\n{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 5,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. Dilution risk is negated by an active $300M buyback program, but the setup lacks the breadth of catalysts and structural support required to clear the bar.\"\n}\n```\nWait, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\" I will remove the ```json wrapper.\nFinal check of the text: matches exactly.\nProceeds. \n[Output Generation] -> Direct JSON. \n(Self-Correction/Note during thought)\nI should verify the \"dilution\" anti-signal gate. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" My reason does articulate it. That satisfies the constraint.\nAll good.\nOutput matches. \nProceeds. \n[Final Output Generation] -> JSON string. \n(Note: I will make sure the keys match exactly.)\nDone. \n[Output] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 5,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. Dilution risk is negated by an active $300M buyback program, but the setup lacks the breadth of catalysts and structural support required to clear the bar.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 5,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. Dilution risk is negated by an active $300M buyback program, but the setup lacks the breadth of catalysts and structural support required to clear the bar.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 5,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. Dilution risk is negated by an active $300M buyback program, but the setup lacks the breadth of catalysts and structural support required to clear the bar.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 63178,
  "stop_reason": "stop",
  "completed_at": "2026-05-20T22:11:43.295Z"
}